The literature dealing with the natural history of cervical intraepithelial neoplasia (CIN) since
1950 is reviewed, in particular from the viewpoint of regression, persistence, and …

Background Reaching the therapeutic target of remission or low-disease activity has
improved outcomes in patients with rheumatoid arthritis (RA) significantly. The treat-to-target …

Targeted biologic therapies have revolutionised treatment of immune-mediated
inflammatory diseases (IMIDs) due to their efficacy, speed of onset and tolerability. The …

Background—Rheumatoid arthritis (RA) is a systemic inflammatory condition associated
with increased cardiovascular risk. This is not fully explained by traditional risk factors, but …

BACKGROUND The actions of the extracellular‐matrix degrading enzymes, matrix
metalloproteinases (MMPs), are implicated in tumorigenesis. The cellular localization of …

Background Non-adherence impacts negatively on patient health outcomes and has
associated economic costs. Understanding drivers of treatment adherence in immune …

Abstract Objective. Rituximab (RTX), a B-cell depleting mAb, has been reported to cause
pulmonary toxicity in many patients. As the use of this biologic is increasing, we have …

Eight mesonephric adenocarcinomas of the uterine cervix, four of which had a malignant
spindle-cell component, occurred in women aged 34 to 71 (median 43, mean 54.5) years …

Tocilizumab, a monoclonal antibody targeting the IL-6 receptor, has recently been added to
the therapeutic armamentarium against rheumatoid arthritis (RA). Despite its overall safety …

Objective. Lung disease is commonly encountered in rheumatological practice either as a
manifestation of the underlying condition or as a consequence of using disease-modifying …